Logotype for Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding (TNXP) investor relations material

Tonix Pharmaceuticals Holding Stifel 2025 Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Tonix Pharmaceuticals Holding Corp
Stifel 2025 Healthcare Conference summary13 Nov, 2025

Financial and operational highlights

  • Ended September with $190 million in cash, no debt, and a simple cap table; cash runway extends into Q1 2027, fully funding the product launch.

  • Commercial launch of newly approved fibromyalgia treatment Tonmya set for before end of November, with experienced sales team and omnichannel prescriber engagement.

  • Tonmya added to existing wholesaler and specialty pharmacy contracts; robust patient access and support services planned at launch.

  • 25,000 healthcare providers write 70% of fibromyalgia prescriptions; 90 sales reps to target 70% of these prescribers.

  • Recent acquisition of two acute headache products provided commercial foundation for Tonmya launch.

Product and market insights

  • Tonmya is the first new fibromyalgia drug approved in over 15 years, with unique sublingual cyclobenzaprine formulation and patent exclusivity until 2034.

  • Addresses significant unmet need: 10 million Americans affected, only 3 million diagnosed and treated; high dissatisfaction with current therapies and high off-label opioid use.

  • Tonmya’s efficacy demonstrated by higher responder rates in clinical trials and favorable tolerability profile, with minimal withdrawal due to side effects.

  • Commercial strategy includes proportional pricing for different patient groups and early prescriber outreach.

Pipeline and R&D updates

  • Multiple pipeline programs advancing: TNX-102 SL for acute stress disorder (enrolling), major depressive disorder (study starts next summer), and prior PTSD studies provided strong mechanistic rationale.

  • Anti-CD40 ligand antibody completed phase 1, phase 2 kidney transplant study to start in first half of next year in partnership with Mass General Hospital.

  • TNX-4800, a long-acting antibody for Lyme disease, licensed from University of Massachusetts, phase 2 ready, offers immediate and season-long protection.

  • Intranasal oxytocin/magnesium for Prader-Willi syndrome to enter pivotal study in second half of next year, supported by compelling animal data.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Tonix Pharmaceuticals Holding earnings date

Logotype for Tonix Pharmaceuticals Holding Corp
Q4 202513 Mar, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Tonix Pharmaceuticals Holding earnings date

Logotype for Tonix Pharmaceuticals Holding Corp
Q4 202513 Mar, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing therapies for central nervous system disorders, rare diseases, and infectious diseases. The company’s pipeline includes treatments for conditions such as post-traumatic stress disorder (PTSD), fibromyalgia, and long COVID. Tonix Pharmaceuticals also explores vaccine and antiviral drug candidates for infectious disease prevention and treatment. The company is headquartered in Chatham, New Jersey, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage